Avelumab with axitinib for untreated advanced or metastatic renal cell carcinoma – final appraisal document

In DRAFT guidance, NICE recommends avelumab with axitinib for use within the Cancer Drugs Fund as an option for untreated advanced renal cell carcinoma in adults. It is recommended only if the conditions in the managed access agreement for avelumab with axitinib are followed.


National Institute for Health and Care Excellence